April 8, 2024 Team Rxtrospect CARVYKTI Becomes First and Only BCMA-Targeted Treatment Approved by the U.S. FDA in Second-line Multiple Myeloma April 8, 2024 Team Rxtrospect Schedule Demo Team Rxtrospect